Biotechnology USA-based Ocugen’s shares were down 31% to $2.27, in premarket trading on Friday, as the company announced that the US Food and Drug Administration (FDA), at this time, has declined to issue an emergency use authorization (EUA) for COVAXIN (BBV152) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals two to 18 years of age. 7 March 2022